OTLK Stock Hopes For FDA Approval Of Wet AMD Drug

Outlook Therapeutics' Lytenava treats wet age-related macular degeneration (AMD).

FDA decision on Lytenava follows two previous rejections.

Retail investors speculate a favorable verdict could boost OTLK stock.

The therapy targets an ophthalmic condition using a bevacizumab-vikg formulation.